(Total Views: 618)
Posted On: 05/10/2025 9:38:30 PM
Post# of 154759
Here we get another mention. Nothing too exciting though.
"Leronlimab, a CCR5 antagonist owned by CytoDyn Inc, indicated for HIV infection, triple-negative breast cancer (TNBC), and nonalcoholic steatohepatitis (NASH), is also in Phase II/III stages of multiple clinical trials with potential for future commercialization."
https://kactusbio.com/blogs/news/the-landscap...edXL1dJj-_
(10)
(0)
